Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels

D'Amico, 2002, Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer, J Clin Oncol, 20, 4567, 10.1200/JCO.2002.03.061 Norgaard, 2010, Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007), J Urol, 184, 162, 10.1016/j.juro.2010.03.034 Coleman, 2006, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res, 12, 6243s, 10.1158/1078-0432.CCR-06-0931 Sturge, 2011, Bone metastasis in prostate cancer: emerging therapeutic strategies, Nat Rev Clin Oncol, 8, 357, 10.1038/nrclinonc.2011.127 Crawford, 2013, The utility of prostate-specific antigen in the management of advanced prostate cancer, BJU Int, 112, 548, 10.1111/bju.12061 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Ou, 2003, Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml, Jpn J Clin Oncol, 33, 574, 10.1093/jjco/hyg104 Feneley, 2001, Indicators of pathologic stage of prostate cancer and their use in clinical practice, Urol Clin North Am, 28, 443, 10.1016/S0094-0143(05)70154-3 Rodrigues, 2011, Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials, Int J Radiat Oncol Biol Phys, 80, 445, 10.1016/j.ijrobp.2010.02.034 Roach, 2000, Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials, Int J Radiat Oncol Biol Phys, 47, 617, 10.1016/S0360-3016(00)00577-0 Alexander, 2011, Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) >40 ng/ml: prognostic significance of the preradiation PSA nadir, Int J Radiat Oncol Biol Phys, 81, e713, 10.1016/j.ijrobp.2010.11.068 Logothetis, 2008, Understanding the biology of bone metastases: key to the effective treatment of prostate cancer, Clin Cancer Res, 14, 1599, 10.1158/1078-0432.CCR-07-4603 Armstrong, 2009, Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature, Oncologist, 14, 816, 10.1634/theoncologist.2009-0043 Smith, 2011, Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer, Cancer, 117, 2077, 10.1002/cncr.25762 Demers, 2000, Biochemical markers and skeletal metastases, Cancer, 88, 2919, 10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z Coleman, 2005, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid, J Clin Oncol, 23, 4925, 10.1200/JCO.2005.06.091 Smaletz, 2002, Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration, J Clin Oncol, 20, 3972, 10.1200/JCO.2002.11.021 Chodak, 1991, Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex study group, JAMA, 265, 618, 10.1001/jama.1991.03460050072023 Halabi, 2003, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 21, 1232, 10.1200/JCO.2003.06.100 Kwak, 2002, Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer, J Urol, 168, 995, 10.1016/S0022-5347(05)64559-4 Sasaki, 2011, Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis, Prostate Cancer Prostatic Dis, 14, 248, 10.1038/pcan.2011.14 Scher, 2011, End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice, J Clin Oncol, 29, 3695, 10.1200/JCO.2011.35.8648 Saad, 2014, Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid, Eur Urol, 65, 146, 10.1016/j.eururo.2012.05.007 Ross, 2008, Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect, Cancer, 112, 1247, 10.1002/cncr.23304 Hong, 2012, Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer, Korean J Urol, 53, 607, 10.4111/kju.2012.53.9.607 Morote, 2005, Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer, Int J Biol Markers, 20, 209, 10.1177/172460080502000403 Choueiri, 2009, Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy, Cancer, 115, 981, 10.1002/cncr.24064 Stamey, 1989, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients, J Urol, 141, 1088, 10.1016/S0022-5347(17)41177-3 Furuya, 1998, Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer, Urol Int, 60, 28, 10.1159/000030199 Park, 2009, Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer, J Urol, 181, 2520, 10.1016/j.juro.2009.01.104